Table 1.
Overview Regarding Expression of Cell-Specific Markers, Basal Lamina and Extracellular Matrix Components in Normal Vessels and in Glomeruloid Bodies (GBs) at Different Stages of Their Evolution
| Antibody and source | Normal microvessels 0 days | Primitive GB 3–4 days | Mature GB 7–10 days | Devolving GB 14–21 days | End stage >28 days |
|---|---|---|---|---|---|
| Endothelium | |||||
| CD31; Pharmingen, San Diego CA (mAb) 14,15 | + | + | + | + | + |
| VE cadherin; Pharmingen (mAb) 16 | + | − | − | −/+ | + |
| VEGFR-2 protein; Drs. Brekken/Thorpe (pAb) | + | + | + | + | + |
| Neuropilin; Oncogene, Cambridge, MA (pAb) | − | − | − | −/+ | − |
| Pericytes | |||||
| NG2; Chemicon, Temecula CA (mAb) 17,18 | −/+ | − | + | + | + |
| α-SMA; Sigma, St. Louis MO (mAb clone 1A4) 19 | + | − | −/+ | + | + |
| PDGF β-receptor; Santa Cruz (mAb clone 958) 20 | −/+ | −/+ | + | + | + |
| Smooth muscle myosin; Sigma (mAb clone hSM-V) 21 | −/+ | − | − | −/+ | −/+ |
| α and γ-actin; DAKO (mAb clone HHF) 22,23 | −/+ | − | − | −/+ | −/+ |
| Calponin; Sigma (mAb clone hCP) 24,25 | −/+ | − | − | −/+ | −/+ |
| Desmin; Chemicon (mAb) | −/+ | − | − | −/+ | −/+ |
| Macrophages | |||||
| F4/80; Serotec, Raleigh NC (mAb) | − | − | + | + | − |
| HLA class II; DAKO (mAb clone CR3/43) 26 | − | − | + | + | − |
| Basal Lamina | |||||
| Entactin; Chemicon mAb (mAb) 27 | + | + | + | + | + |
| Perlecan; mAb Chemicon (mAb) 28 | + | + | + | + | + |
| Laminin; mAb Chemicon (mAb) 29 | + | + | + | + | + |
| Collagen IV; Chemicon (mAb) 30 | + | + | + | + | + |
| Extracellular matrix | |||||
| Fibrillar collagen, Masson trichrome stain (Sigma) | + | − | − | −/+ | + |
| Fibrin, anti-fibrinogen; DAKO (pAb) 31 | − | − | + | + | −/+ |
+, all cells/structures positive; −/+, focal expression; −, no detectable expression. mAb, monoclonal antibody; pAb, polyclonal antibody.